Syndecans, including SDC1, exhibit variable expression in several solid tumors and hematologic cancers, with high expression of SDC1 in the cytoplasm of tumor cells correlating with better patient survival [55]. Here, SDC1 is linked to hematopoietic and lymphoid cell neoplasm.